BMBeatriz Moreno

Beatriz Moreno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beatriz Moreno has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Pablo Villoslada

    Affiliations Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain, Hospital del Mar Research Institute, Barcelona, Spain

    3 shared publications
  • Albert Giralt

    Departament de Biomedicina, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain

    1 shared publication
  • Begoña Fernández-Díez

    Center of Neuroimmunology, Institut d'investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) - Hospital Clinic of Barcelona, Barcelona, Spain

    1 shared publication
  • Carlos Matute

    Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Spain

    1 shared publication
  • Carmen Espejo

    Servei de Neurologia-Neuroimmunologia, Centre d’ Esclerosi Múltiple de Catalunya, (Cemcat), Vall d’ Hebron Institut de Recerca, Vall d’ Hebron Hospital Universitari, Universitat Autònoma de Barcelona, Spain

    1 shared publication
  • Carmen Guaza

    1 shared publication

Latest Publications

  • Open Access

    Differential Neuroprotective Effects of 5′-Deoxy-5′-Methylthioadenosine

    by Beatriz Moreno, Iciar Lopez, Begoña Fernández-Díez, Miroslav Gottlieb, Carlos Matute, María Victoria Sánchez-Gómez, María Domercq, Albert Giralt, Jordi Alberch, Kevin W. Collon, et al.

    5′-deoxy-5′-methylthioadenosine (MTA) is an endogenous compound produced through the metabolism of polyamines. The therapeutic potential of MTA has been assayed mainly in liver diseases and, more recently, in animal models of multiple sclerosis. The aim of this study was to determine the neuroprotective effect of this molecule in vitro and to assess whether MTA can cross the blood brain barrier (BBB) in order to also analyze its potential neuroprotective efficacy in vivo. Neuroprotection was assessed in vitro using models of excitotoxicity in primary neurons, mixed astrocyte-neuron and primary oligodendrocyte cultures. The capacity of MTA to cross the BBB was measured in an artificial membrane assay and using an in vitro cell model. Finally, in vivo tests were performed in models of hypoxic brain damage, Parkinson's disease and epilepsy. MTA displays a wide array of neuroprotective activities against different insults in vitro. While the data from the two complementary approaches adopted indicate that MTA is likely to cross the BBB, the in vivo data showed that MTA may provide therapeutic benefits in specific circumstances. Whereas MTA reduced the neuronal cell death in pilocarpine-induced status epilepticus and the size of the lesion in global but not focal ischemic brain damage, it was ineffective in preserving dopaminergic neurons of the substantia nigra in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-mice model. However, in this model of Parkinson's disease the combined administration of MTA and an A2A adenosine receptor antagonist did produce significant neuroprotection in this brain region. MTA may potentially offer therapeutic neuroprotection.


  • Open Access

    Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity

    by Sara Martinez-Pasamar, Elena Abad, Beatriz Moreno, Nieves Velez de Mendizabal, Ivan Martinez-Forero, Jordi Garcia-Ojalvo, Pablo Villoslada

    Background: Multiple Sclerosis (MS) is considered a T-cell-mediated autoimmune disease with a prototypical oscillatory behavior, as evidenced by the presence of clinical relapses. Understanding the dynamics of immune cells governing the course of MS, therefore, has many implications for immunotherapy. Here, we used flow cytometry to analyze the time-dependent behavior of antigen-specific effector (Teff) and regulatory (Treg) T cells and microglia in mice model of MS, Experimental Autoimmune Encephalomyelitis (EAE), and compared the observations with a mathematical cross-regulation model of T-cell dynamics in autoimmune disease. Results: We found that Teff and Treg cells specific to myelin olygodendrocyte glycoprotein (MOG) developed coupled oscillatory dynamics with a 4- to 5-day period and decreasing amplitude that was always higher for the Teff populations, in agreement with the mathematical model. Microglia activation followed the oscillations of MOG-specific Teff cells in the secondary lymphoid organs, but they were activated before MOG-specific T-cell peaks in the CNS. Finally, we assessed the role of B-cell depletion induced by anti-CD20 therapy in the dynamics of T cells in an EAE model with more severe disease after therapy. We observed that B-cell depletion decreases Teff expansion, although its oscillatory behavior persists. However, the effect of B cell depletion was more significant in the Treg population within the CNS, which matched with activation of microglia and worsening of the disease. Mathematical modeling of T-cell cross-regulation after anti-CD20 therapy suggests that B-cell depletion may influence the dynamics of T cells by fine-tuning their activation. Conclusions: The oscillatory dynamics of T-cells have an intrinsic origin in the physiological regulation of the adaptive immune response, which influences both disease phenotype and response to immunotherapy.


    • 16 January 2012
      • Vol. 54  (2) , 114-24

    [Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis].

    by Beatriz Moreno, Carmen Espejo, Leyre Mestre, Margarita Suardiaz, Diego Clemente, Fernando De Castro, Óscar Fernández-Fernández, Xavier Montalban, Pablo Villoslada, Carmen Guaza, et al.

    The advance in the achievement of effective therapies for multiple sclerosis (MS), the definition of appropriate therapeutic windows and to establish better diagnostic and prognostic biomarkers have become a challenging task for both researchers and clinicians. Some pitfalls in clinical trials might be related to lack of adequacy of the preclinical studies in MS experimental animal models. To standardize the methodological protocols of experimental models by developing a set of guidelines for preclinical studies by groups of experts from REEM (Spanish Network for MS). A guide with recommendations for the application of MS models including a detailed assessment of appropriate experimental models taking into account the objective of the study that has been presented. Standards and quality criteria necessary in a preclinical study have been included. Standardized animal models of MS are essential to increase the success of the preclinical findings in order to transfer them to the clinical practice.


  • Neuroprotective Therapies for Multiple Sclerosis

    by Beatriz Moreno, Pablo Villoslada

    Multiple sclerosis (MS) is considered to be an autoimmune disease that is caused by the immune system attacking the central nervous system (CNS) leading to myelin loss and axonal damage, resulting in long-term disability. The pathophysiology of MS is complex with involvement of genetic and environmental factors that define the susceptibility to generate the autoimmune attack. In the last decade, several immunomodulatory drugs have been approved, including recombinant proteins such as interferon-beta, monoclonal antibodies such as natalizumab, or small chemicals including glatiramer acetate. In addition, there is a wide pipeline of new immunomodulators finishing Phase II or III trials. However, at present there are no approved treatments that directly reduce nervous system damage or enhance its repair. Novel neuroprotective agents have been identified in pre-clinical studies but their development is being prevented by the absence of appropriate understanding of the mechanisms of CNS damage by inflammation as well as by the lack of clinical platforms to test them. In this review, we describe the different mechanisms of axonal injury and discuss some of the principal therapeutic candidates that could provide neuroprotection in MS.